News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Scancell Signs New Agreement With Biovation To DeImmunise SC101



10/19/2005 5:12:16 PM

Nottingham UK January 11th 2005 - Scancell Ltd, the Nottingham-based cancer therapeutics company, has announced that it has secured an agreement with Biovation under which Biovation will apply their DeImmunisation technology to up to two further monoclonal antibodies (MAbs) in Scancell’s portfolio, including SC101, Scancell’s anti-cancer MAb against Lewisy/b.


Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES